Acute Human Study of Intravenously Infused WR-2823. Volume II.
OKLAHOMA UNIV HEALTH SCIENCES CENTER OKLAHOMA CITY MCALESTER DIV OF CLINICAL PHARMACOLOGY
Pagination or Media Count:
WR-2823 has been shown in animal studies to possess alpha-adrenergic blocking activity and increased survival in dogs with hemorrhagic and endotoxin shock. The purpose of this study was to evaluate its safety, tolerance and effect on blood pressure and heart rate in healthy male volunteers. It was an open study in which the dose was progressively increased by intravenous infusion. Thirty-six subjects participated as three randomly assigned to each of twelve dose levels ranging from five to 2880 mg. There was no significant change in supine blood pressure. There was transient postural hypotension at higher dose levels. Supine and standing heart rate increased in a dose related fashion and that effect was of longer duration than the postural hypotension. Electrocardiographic tracings are presented in this appendix. Modified author abstract